Semaglutide
The cited U.S. label includes specified weight-management indications and treatment of noncirrhotic MASH with moderate to advanced fibrosis in adults. The MASH indication received accelerated approval; continued approval may depend on confirmatory evidence of clinical benefit. See the label for exact populations and limitations.
Wegovy (semaglutide) · source checked 2026-11-04. The linked document is dated; consult current FDA labeling for changes.
FDA Wegovy prescribing information, 2025Covered registry studies
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Ongoing, no longer enrolling
Registry enrollment: 1,205 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Completed
Registry enrollment: 751 participants
Study ages: 18 Years and older
Results posted Nov 26, 2025
Read trial record and resultsChecked Nov 17, 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Completed
Registry enrollment: 1,024 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Completed
Registry enrollment: 1,023 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Completed
Registry enrollment: 1,133 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 2 · Enrolling participants
Planned enrollment: 330 participants
Study ages: 18 Years and older
Recruiting sites listed in: United States
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Enrolling participants
Planned enrollment: 660 participants
Study ages: 18 Years and older
Recruiting sites listed in: United States
No results-posting date in this record
Read trial record and resultsChecked Nov 16, 2026
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Enrolling participants
Planned enrollment: 1,300 participants
Study ages: 18 Years and older
Recruiting sites listed in: Canada, United States
No results-posting date in this record
Read trial record and resultsChecked Nov 16, 2026
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
US: FDA approval not reviewed here
The registry reports not yet recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Not yet enrolling
Planned enrollment: 1,200 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
US: FDA approval not reviewed here
The registry reports not yet recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Not yet enrolling
Planned enrollment: 1,060 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026